Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 533,542	$ 990,457
Accounts receivable, net of allowance of $2,500 and $0, at December 31, 2017 and September 30, 2018	112,419	94,413
Inventories	46,194	53,973
Prepaid expenses and other current assets	60,173	20,000
Total current assets	752,328	1,158,843
Leasehold improvements and equipment, net of depreciation	125,219	108,865
Other non-current assets	35,215	32,530
Deferred offering cost	176,123	195,182
Total assets	1,088,885	1,495,420
Current liabilities:
Accounts payable and accrued expenses	361,063	224,105
Convertible notes and notes payable	1,383,108	5,248,847
Lines of credit	430,000
Discount on debt obligations, net of amortization	(345,858)	(1,257,182)
Total current liabilities	1,828,313	4,215,770
Long-term liabilities:
Convertible notes and note payable	460,000	1,539,271
Discount on debt obligations, net of amortization	(218,556)	(850,000)
Total liabilities	2,069,757	4,905,041
COMMITMENTS AND CONTINGENCIES (Note 10)
STOCKHOLDERS’ EQUITY (DEFICIT):
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at December 31, 2017 and September 30, 2018
Common stock, $.00067 Par value, 200,000,000 and 400,000,000 shares authorized, 104,164,465 and 132,036,574 shares issued, at December 31, 2017 and September 30, 2018	88,617	69,871
Additional paid-in capital	108,214,683	97,093,144
Accumulated deficit	(109,591,476)	(101,204,846)
Accumulated other comprehensive loss	(67,373)	(62,489)
Total Biolargo, Inc. and Subsidiaries stockholders’ equity (deficit)	(1,355,549)	(4,104,320)
Non-controlling interest (Note 8)	374,677	694,699
Total stockholders’ equity (deficit)	(980,872)	(3,409,621)
Total liabilities and stockholders’ equity (deficit)	$ 1,088,885	$ 1,495,420